Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Change in Accured Expenses (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Change in Accured Expenses for 3 consecutive years, with -$1.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 125.12% to -$1.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.9 million, a 105.49% decrease, with the full-year FY2024 number at $35.9 million, up 37.64% from a year prior.
  • Change in Accured Expenses was -$1.5 million for Q3 2025 at Inhibrx Biosciences, up from -$4.3 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $21.8 million in Q2 2024 to a low of -$4.3 million in Q2 2025.
  • A 3-year average of $7.1 million and a median of $6.2 million in 2023 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: decreased 5.05% in 2024, then plummeted 125.12% in 2025.
  • Inhibrx Biosciences' Change in Accured Expenses stood at $17.4 million in 2023, then plummeted by 65.33% to $6.0 million in 2024, then tumbled by 125.12% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Change in Accured Expenses are -$1.5 million (Q3 2025), -$4.3 million (Q2 2025), and $2.9 million (Q1 2025).